{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:08:57Z","timestamp":1768450137755,"version":"3.49.0"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,24]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>This review aims to provide an update on current pharmacological agents for the management of generalized myasthenia gravis (MG).<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>MG is an autoimmune disease characterized by impaired neuromuscular transmission and muscle weakness. Most patients have autoimmune antibodies to the nicotinic acetylcholine receptor, with treatments aimed at eliminating or decreasing levels of autoantibodies. Limitations of current treatments for generalized MG include limited efficacy and serious adverse effects, indicating a continued need for new treatments. Efgartigimod alfa, a biologic newly approved by the Food and Drug Administration, provides a novel treatment option for patients with chronic generalized MG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>While the landscape for treatment of generalized MG has expanded over recent years, there is still an unmet need for patients for whom multiple lines of treatment have failed. The introduction of neonatal Fc receptor antagonists such as efgartigimod alfa may have an immediate impact in patients for whom standard-of-care therapy has failed.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ajhp\/zxad035","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T06:31:46Z","timestamp":1676269906000},"page":"652-662","source":"Crossref","is-referenced-by-count":4,"title":["An update of the pharmacological treatment options for generalized myasthenia gravis in adults with anti\u2013acetylcholine receptor antibodies"],"prefix":"10.1093","volume":"80","author":[{"given":"Tanya R","family":"Riley","sequence":"first","affiliation":[{"name":"Wingate University School of Pharmacy , Hendersonville, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janine S","family":"Douglas","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Wang","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiarra M","family":"Bowser","sequence":"additional","affiliation":[{"name":"Wingate University School of Pharmacy , Hendersonville, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"issue":"4","key":"2023060913410525000_CIT0001","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"2023060913410525000_CIT0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.25122\/jml-2020-0145","article-title":"The epidemiology of myasthenia gravis","volume":"14","author":"Bubuioc","year":"2021","journal-title":"J Med Life"},{"key":"2023060913410525000_CIT0003","author":"National Organization for Rare Disorders","year":"2022"},{"issue":"11","key":"2023060913410525000_CIT0004","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology, and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"issue":"17","key":"2023060913410525000_CIT0005","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1007\/s00018-012-1209-9","article-title":"Structural mechanisms of the agrin-LRP4-MuSK signaling pathway in neuromuscular junction differentiation","volume":"70","author":"Zong","year":"2013","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2023060913410525000_CIT0006","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-2004-829585","article-title":"Pathophysiology of myasthenia gravis","volume":"24","author":"Hughes","year":"2004","journal-title":"Semin Neurol"},{"issue":"26","key":"2023060913410525000_CIT0007","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2023060913410525000_CIT0008","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"2023060913410525000_CIT0009","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"issue":"3","key":"2023060913410525000_CIT0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/s-0032-1329200","article-title":"Myasthenia gravis","volume":"32","author":"Silvestri","year":"2012","journal-title":"Semin Neurol"},{"issue":"1","key":"2023060913410525000_CIT0011","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/1744666X.4.1.43","article-title":"Effect of complement and its regulation on myasthenia gravis pathogenesis","volume":"4","author":"Kusner","year":"2008","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"2023060913410525000_CIT0012","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000279334","article-title":"The incidence of myasthenia gravis: a systematic literature review","volume":"34","author":"McGrogan","year":"2010","journal-title":"Neuroepidemiology"},{"issue":"3","key":"2023060913410525000_CIT0013","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"6","key":"2023060913410525000_CIT0014","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"issue":"16","key":"2023060913410525000_CIT0015","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1212\/WNL.0000000000009294","article-title":"Practice advisory: thymectomy for myasthenia gravis (practice parameter update): report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"94","author":"Gronseth","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"2023060913410525000_CIT0016","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/mus.26404","article-title":"Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis","volume":"59","author":"Clifford","year":"2019","journal-title":"Muscle Nerve"},{"issue":"2","key":"2023060913410525000_CIT0017","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol Clin"},{"issue":"1","key":"2023060913410525000_CIT0018","doi-asserted-by":"crossref","first-page":"102712","DOI":"10.1016\/j.autrev.2020.102712","article-title":"Update in immunosuppressive therapy of myasthenia gravis","volume":"20","author":"Lascano","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"5","key":"2023060913410525000_CIT0019","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/WCO.0000000000000858","article-title":"Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies","volume":"33","author":"Dalakas","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"2023060913410525000_CIT0020","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3389\/fneur.2020.00604","article-title":"A practical approach to managing patients with myasthenia gravis\u2014opinions and a review of the literature","volume":"11","author":"Farrugia","year":"2020","journal-title":"Front Neurol"},{"key":"2023060913410525000_CIT0021","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jns.2016.08.057","article-title":"Maintenance immunosuppression in myasthenia gravis","volume":"369","author":"Gotterer","year":"2016","journal-title":"J Neurol Sci"},{"key":"2023060913410525000_CIT0022","article-title":"Eculizumab.","year":"2020"},{"key":"2023060913410525000_CIT0023","article-title":"Ravulizumab.","volume-title":"Lexicomp Online [proprietary data]","year":"2020"},{"key":"2023060913410525000_CIT0024"},{"key":"2023060913410525000_CIT0025","article-title":"Efgartigimod alfa.","volume-title":"Lexicomp Online [proprietary data]","year":"2020"},{"issue":"10","key":"2023060913410525000_CIT0026","first-page":"D006986","article-title":"Acetylcholinesterase inhibitor treatment for myasthenia gravis","volume":"2014","author":"Mehndiratta","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2023060913410525000_CIT0027","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/11593300-000000000-00000","article-title":"Treatment of myasthenia gravis: focus on pyridostigmine","volume":"31","author":"Maggi","year":"2011","journal-title":"Clin Drug Investig"},{"key":"2023060913410525000_CIT0028","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann NY Acad Sci"},{"issue":"18","key":"2023060913410525000_CIT0029","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/14656566.2019.1682548","article-title":"Current pharmacotherapeutic options for myasthenia gravis","volume":"20","author":"Barnett","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"2023060913410525000_CIT0030","first-page":"CD002828","article-title":"Corticosteroids for myasthenia gravis","volume":"2005","author":"Schneider-Gold","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2023060913410525000_CIT0031","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial","volume":"53","author":"Benatar","year":"2016","journal-title":"Muscle Nerve"},{"issue":"6","key":"2023060913410525000_CIT0032","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"issue":"772","key":"2023060913410525000_CIT0033","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/pgmj.66.772.102","article-title":"Long term treatment of myasthenia gravis with azathioprine","volume":"66","author":"Fonseca","year":"1990","journal-title":"Postgrad Med J"},{"issue":"5","key":"2023060913410525000_CIT0034","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle Nerve"},{"issue":"6","key":"2023060913410525000_CIT0035","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"2023060913410525000_CIT0036","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"issue":"12","key":"2023060913410525000_CIT0037","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"N Engl J Med"},{"key":"2023060913410525000_CIT0038","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann NY Acad Sci"},{"issue":"3","key":"2023060913410525000_CIT0039","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","article-title":"Efficacy of low-dose FK506 in the treatment of myasthenia gravis\u2014a randomized pilot study","volume":"53","author":"Nagane","year":"2005","journal-title":"Eur Neurol"},{"issue":"9","key":"2023060913410525000_CIT0040","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023060913410525000_CIT0041","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol"},{"issue":"1","key":"2023060913410525000_CIT0042","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"2023060913410525000_CIT0043","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.10133","article-title":"Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis","volume":"26","author":"De Feo","year":"2002","journal-title":"Muscle Nerve"},{"issue":"1-2","key":"2023060913410525000_CIT0044","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2013.10.043","article-title":"Maintenance IVIg therapy in myasthenia gravis does not affect disease activity","volume":"338","author":"Hellmann","year":"2014","journal-title":"J Neurol Sci"},{"key":"2023060913410525000_CIT0045","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study","author":"Nowak","year":"2021","journal-title":"Neurology"},{"issue":"12","key":"2023060913410525000_CIT0046","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"issue":"1","key":"2023060913410525000_CIT0047","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"2023060913410525000_CIT0048"},{"issue":"18 suppl","key":"2023060913410525000_CIT0049","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1212\/WNL.98.18_supplement.791","article-title":"Efficacy and safety of ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG study (P1-1.Virtual)","volume":"98","author":"Vu","year":"2022","journal-title":"Neurology"},{"key":"2023060913410525000_CIT0050","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal Fc receptor (FcRn): a misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front Immunol"},{"issue":"10","key":"2023060913410525000_CIT0051","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"issue":"3","key":"2023060913410525000_CIT0052","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2023060913410525000_CIT0053","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","article-title":"Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis","volume":"10","author":"Gable","year":"2020","journal-title":"Front Immunol"},{"issue":"23","key":"2023060913410525000_CIT0054","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"2023060913410525000_CIT0055","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"issue":"6","key":"2023060913410525000_CIT0056","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial","volume":"96","author":"Bril","year":"2021","journal-title":"Neurology"},{"key":"2023060913410525000_CIT0057"},{"key":"2023060913410525000_CIT0058","author":"UCB","year":"2021"},{"issue":"6","key":"2023060913410525000_CIT0059","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/mus.27064","article-title":"Myasthenia gravis and pregnancy","volume":"62","author":"Grover","year":"2020","journal-title":"Muscle Nerve"},{"key":"2023060913410525000_CIT0060","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3389\/fneur.2020.00554","article-title":"Myasthenia gravis can have consequences for pregnancy and the developing child","volume":"11","author":"Gilhus","year":"2020","journal-title":"Front Neurol"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxad035\/49600004\/zxad035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/11\/652\/50521970\/zxad035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/11\/652\/50521970\/zxad035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:47:12Z","timestamp":1728866832000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/80\/11\/652\/7034872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":60,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,2,13]]},"published-print":{"date-parts":[[2023,5,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxad035","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,2,13]]}}}